RESEARCH

Brief cognitive behavior therapy for stigmatization, depression, quality of life, social support and adherence to treatment among patients with HIV/AIDS: a randomized control trial

Qasir Abbas[1*], Mehru Nisa[1], Muhammad Umar Khan[1], Nida Anwar[2], Sumayah Aljhani[3], Zoobia Ramzan[2] and Mafia Shahzadi[1]

Abstract

Objective Individuals living with HIV/AIDs are at a high risk of many problems like depression, stigma, quality of life, decreased adherence to treatment, and lack of social support. The present study aimed to investigate the impact of brief-cognitive behavior therapy (B-CBT) on reducing depression and stigma and improving treatment adherence, quality of life, and social support among patients with HIV/AIDS attending antiretroviral therapy (ART).

Materials and methods This randomized clinical trial was conducted at ART Clinic in the Tehsil Headquarters Hospital Shahkot Nankana Sahib from July 2021 to October 2021. After baseline screening, 126 patients met the eligibility criteria and 63 were allocated to the experimental group (EXPg = 63) and 63 to waitlist-control group (WLCg = 63). Participants' age range was from 20 to 55 years. Participants who were taking ART treatment were enrolled for the CBT treatment. Before this, all the participants completed a baseline assessment to ensure a level of severity and diagnosis. A total of eight CBT based therapeutic sessions were conducted individually with EXPg. To assess the outcomes among patients receiving ART, we used Demographic form, Patient health questionnaire, HIV stigma scale, General medication adherence scale, Multidimensional scale of perceived social support, and WHOQOL BREF scale.

Results Findings suggest that B-CBT significantly reduced the level of depression (i.e. F (1, 78) = 101.38, p < .000, η2 = .599), and social stigma (i.e. F (1, 78) = 208.47, p < .000, η2 = .787) among patients with HIV/AIDS. Furthermore, CBT substantially improved the level of adherence to treatment (i.e. F(1,78) = 24.75, p < .000, η2 = .503), social support (i.e. F (1, 78) = 128.33, p < .000, η2 = .606), and quality of life (i.e. F (1, 78) = 373.39, p < .000, η2 = .837) among patients with HIV/AIDS. Significant mean difference M(SD) on PHQ at post-analysis in the EXPg vs. WLCg was seen 1.22(0.47) vs. 2.30(0.68) and similarly, on MPSS at a post-analysis in the EXPg vs. WLCg 2.85(0.36) vs. 1.70(0.51) which indicates sound therapeutic outcomes.

*Correspondence:
Qasir Abbas
qasirabbas47@yahoo.com
Full list of author information is available at the end of the article

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 2 of 13

Conclusions Cognitive behavioral therapy effectively decreases the level of depression and stigma and enhances the level of social support, quality of life, and adherence to treatment among HIV/AIDS patients. It is concluded that cognitive behavior therapy is an effective treatment approach for patients with HIV/AIDS.

Trial registration Thai clinical trial registry (i.e. TCTR = TCTR20210702002).

Keywords Cognitive behavior therapy, Stigmatization, Depression, Quality of life, Social support, Treatment adherence, Patients with HIV/AIDS

Introduction

HIV/AIDS is a life-long chronic disease with many potentially debilitating symptoms that can reduce one's quality of life [1, 2]. It leads to severe sickness or death [3]. Aside from the symptoms, patients with HIV/AIDS also face various cultural and psychosocial issues (like stigma); this combined suffering makes them increasingly prone to developing depression,,being more stressed and losing hope [4]. Stigma is common in HIV-positive people, diminishing their quality of life and leading to poor clinical outcomes [3]. Internalized HIV-related Stigma may lead to HIV transmission-related risky behaviors such as poor antiretroviral adherence, unsafe sex, avoidance of medical treatment, and a reluctance towards HIV status disclosure in situations where it could pose a risk to themselves or to others [5]. Defining HIV-related Stigma (HRS) is difficult because of the interplay of various factors like personal cognitions, structural inequalities, cultural differences, discrimination by health care providers, and a general fear of discrimination [6]. Internalized Stigma refers to endorsing negative beliefs and misconceptions about HIV/AIDS [7–11].

According to a report published by the United Nations' programme on HIV/AIDS in 2020, HIV/AIDS remains a major public health concern around the world; As per the aforesaid report, 37.7 million people were living with HIV/AIDS,, 1.5 million people were newly infected with it, 680 000 people died from its related illnesses, and 27.5 million people were accessing antiretroviral therapy worldwide. According to the report people living with HIV/AIDS in Asia and the Pacific were around 5.8 million, with 240,000 new HIV/AIDS infections, 130 000 AIDS-related deaths, and 3.7 million accessing treatment. According to the same report, in Pakistan, the number of adults and children living with HIV/AIDS were 200,000 with HIV/AIDS prevalence rate of around 0.2% in the age bracket of 15 to 29 years. and adult and child deaths due to AIDS were 8200, whereas, people living with HIV/AIDS who know their status were 45,000with 24,000 currently receiving ART [12].

One of the major problems usually accompanying HIV/AIDS is major depression (MD); it is highly prevalent in HIV/AIDS infected patients and this psychiatric disorders could increase mortality this strata [13–16] Depression is characterized by a depressed mood, lack of concentration, diminished energy, disturbed sleep, and low self-esteem [17]. There is a an increased risk of HIV/AIDS transmission when the patient does not adhere to ART [18]. ART increases life expectancy and quality of life [19–21]. ART can also reduce the rate of transmission from the patients to others [22]. Depression is a key predictor of poor adherence to HIV/AIDS medication [23]. Social support can be described as the social, psychological, and interpersonal assistance that optimizes health and well-being of an individual's [24]. Perceived social support has been linked with better QOL among people living with HIV [25, 26]. Among patients with HIV/AIDS, a positive association between increased social support and better clinical outcomes has been found [27–29].

Psychotherapy appears to be an effective treatment for adult depression [30, 31]. However, cognitive behavioral approaches to psychotherapy have been found to specifically improve antiretroviral medication adherence and reduce depression in patients with HIV/AIDS [32, 33]. Cognitive-Behavioral Therapy (CBT) has emerged as a highly promising intervention; it is a goal-oriented therapy that focuses on modifying negative thought patterns and behaviors, and by enhancing emotion regulation, problem-solving skills, and positive coping mechanisms [34]. Furthermore, CBT interventions are beneficial in increasing a person's stress coping methods repertoire and, as a result, improving mental health in HIV patients [35, 36]. Adherence to HIV treatment, self-care, and medication can be improved through CBT therapies [30, 32, 37, 38]. Applying cognitive-behavioral techniques enhances medication adherence by addressing negative thinking, fostering adaptive coping skills, and promoting effective problem-solving; this approach helps patients manage their medication side effects and HIV-related stress, resulting in improved health outcomes [38]. Spies et al. [39] found that i cognitive-behavioral therapy (CBT) is effective in reducing depression and improving antiretroviral medication (ART) adherence in patients with HIV/AIDS [32, 39–42]. By combining behavioral and cognitive techniques, CBT targets activity and thinking patterns. [43, 44]. CBT is effective in enhancing social support for HIV/AIDS patients by strengthening support networks and improving interpersonal skills [45, 46]. Both individual and group psychotherapies are effective for reducing depressive

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 3 of 13

symptoms in people with HIV [47]. However, there is a need for a briefer, time-bound, and solution-focused version of psychotherapy for psychological betterment of patients of serious illnesses that does not drain their valuable resources of time and money too much [48–50]. Such a modality of psychological intervention is highly needed in underdeveloped countries like Pakistan owing to limited financial resources available to the patients here [51, 52]. Brief CBT is one such modality of psychotherapy that addresses the psychosocial concerns in only a few number of sessions (usually around 10) and is time-bound [53]. We developed an 8 session version of CBT tailored for the needs of patients with HIV/AIDS by utilizing a combination of classic and brief CBT literature [53, 54].

This study was aimed to see how brief CBT affects HIV patients' psychological health and adherence to ART, because, usually, when people get to know about their HIV positive status, they feel shame. And as HIV/AIDS diagnosis is not considered in a supportive manner in Pakistani society and the families of the diagnosed patient change attitude towards the patient for the worse, so that's why they face many problems [55]. The patients with HIV/AIDS usually internalize the stigma attached to the disease and usually feel mentally disturbed which makes them vulnerable to the development of different psychiatric problems. Therefore, they need psychological treatment. Their quality of life is also affected due to potential HIV/AIDS progression, poor treatment adherence, a lack social support, and comorbid psychiatric problems. In the present study, psychological treatment was given to HIV/AIDS patients in the form of cognitive behaviour therapy to address different problems of theirs. It was aimed at enhancing mental health, decreasing their stigma and depression, and increasing their treatment adherence, social support, and quality of life.

Materials and methods
Study setting
This prospective clinical trial was conducted at Tehsil Headquarter (THQ) hospital providing diagnostic and treatment facilities to patients with HIV/AIDS in Shahkot, Nankana District (Punjab, Pakistan). This was a public sector hospital which has ART clinic that provides free treatment facilities to patients with HIV/AIDS.

Research design
This study was a prospective, randomized control trial (RCT) conducted from 25 May 2021 to December 2022 at a hospital clinic where individuals who have HIV/AIDS are provided with treatment. In this study, we compared the effectiveness of cognitive behavior therapy between experimental and waitlist control groups using pre-and post-test design. The Institutional Review Board of Government College University, Faisalabad, Pakistan, approved the study protocol (IRB) (i.e. Ref. No. GCUF/ERC/2267, dated 17/06/2021). This clinical trial was registered in the Thai clinical trial registry (i.e. TCTR=TCTR20210702002, with URL: https://www.thaiclinicaltrials.org/show/TCTR20210702002) with first registration date 02/07/2021.

Participants
A total of 186 participants diagnosed with HIV/AIDs were recruited for eligibility from THQ Hospital Shahkot, Pakistan. We calculated sample size using G-Power software estimating effect size (f)=0.20, α=0.05, power (1-β error prob.)=0.95 with actual power=0.96 which structured sample size of 48 (for both experimental and waitlist control conditions) [56]. Initially, participants were screened using Patient Health Questionnaire-9, and those who scored≥5 (at least with mild symptoms severity) were enrolled in the treatment. Sixty participants were excluded;; a) 18 patients were excluded due to their comorbid condition with other physical ailments) 12 patients were excluded due to a lack of history of treatment and non-provision of information c) 13 were excluded because their traveling time between their clinic and their home was long and they could not visit the clinic as often as needed, and d) 17 patients were excluded who showed a lack of interest in the study (n=17). Therefore, 126 out of 186 met the inclusion criteria and were then allocated in a ratio of 1:1 to our experimental (n=63) and waitlist-control (n=63) groups (see Fig. 1).

Inclusion and exclusion criteria
In this RCT, diagnosed patients having HIV/AIDS were recruited. The first eligibility criterion was that the enrolled participants must be registered with the ART clinic and must also be receiving ART regularly. Patients' HIV/AIDs diagnosis was made on the basis of medical reports and evaluation. Participants who had initiated their treatment using ART and had completed all HIV/AIDS related medical evaluations, were recruited for this study. Participants were then assessed by our clinical psychologist. The further eligibility criteria were as follows: a) participants availing out-door patients' facility with mean score of≥5 on the PHQ-9 (at least having mild severity of depression or higher) and b) the participants were then cross-checked against set exclusion criteria, thereby excluding pregnant women, participants with substance use disorder, individuals with any physiological comorbidity, and individuals who were availing in-patient services. Participants with any other serious comorbidity

Fig. 1 Flowchart diagram of patients with HIV/AIDs

(i.e., any other serious physiological or psychiatric disease except depression) were excluded from the study. Furthermore, individuals under the age of 20 and over the age of 55 years were also excluded from the study.

Assessment measures
Demographic form
A detailed demographic form and history taking form were used to get personal information (i.e., age, education, socioeconomic level, family system, family members, marital status, employment status, risk transmission, and total earning members), history of illness (i.e. duration of HIV/AIDS, duration of taking current medication, age at the time HIV/AIDS diagnosis, previous treatments, a family member died due to HIV/AIDS, any other family member diagnosed with HIV/AIDS, information about HIV/AIDS).

Patient Health Questionnaire (PHQ-9)
The PHQ-9 was originally developed by Spitzer et al. It was translated and validated into an Urdu version by Ahmad et al., (Cronbach's alpha = 0.91) [57, 58]. The

Urdu version of the PHQ-9 was used in this study. The PHQ is a nine-item self-report measure based on the DSM diagnostic criteria of depressive disorder. It investigates about the presence of different symptom sets of major depressive episodes that were present in an individual during the past two weeks. The PHQ-9 uses a 4-point response scale ranging from not at all (0) to nearly every day (3). Higher scores on the scale indicate the severity of depressive symptoms, and lower scores indicate low severity. The PHQ-9 also provides symptom severity, i.e., none-minimal (0–4), mild (5–9), and moderate (10–14), moderate-severe (15–19) and severe (20–27) respectively. Furthermore, many studies have shown its legitimacy and reliability [57, 58].

HIV Stigma Scale (HSS)
HSS is a 40-item scale was originally developed by Berger et al. [59]. It was translated and validated into an Urdu version by Saif and Shehzad [60]. The Urdu version of HSS was used in the present study. The HSS assesses four factors i.e., personalized stigma,

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 5 of 13

disclosure concerns, negative self-image, and public attitudes. Each item is scored using a 4-point Likert-type scale ranging from "strongly disagree" to "strongly agree". The HSS scores range from 40 to 160. The higher scores indicate the high intensity of stigma. The HSS has good psychometric properties and is a valid and reliable measure [60].

General Medication Adherence Scale (GMAS)

GMAS is originally developed in Urdu Language was used [61]. The GMAS consists of 11 items with four possible options divided into three domains. The first domain is non-adherence due to patient behavior (NAPB), the second domain is non-adherence due to other diseases and pill burdens (ADPB), and the third domain is nonadherence due to financial constraints (NAFC). Each item's score ranges from 0 to 3, and the total sum of all items yields an overall adherence score, which is categorized as high (30–33), good (27–29), partial (17–26), low (11–16), and poor adherence (≤10). The GMAS has good reliability of 0.80 and test–retest reliability of 0.996, respectively [61].

Multidimensional Perceived Social Support Scale (MPSS)

MPPS was originally developed by Zimet et al. [62]. It was translated and validated into an Urdu version by Akhtar et al. [63].The Urdu version of MSPSS was used in the current study. The MPSS is a 12-item, unidimensional questionnaire that assesses how people view their social support system which includes their family, friends, and significant others. Each item is scored on a 7-point scale ranging from "strongly disagree" to "strongly agree". A higher score indicates a higher level of social support. The overall reliability of MPSS is > 0.80 and for subscale 0.82, 0.86, and 0.86 respectively.

WHO Quality of Life Scale-Brief (WHQOL-B)

Urdu version of WHQOL-B was used [64]. The Urdu version of WHQOL-B was used in the present study. WHQOL-B contains two items to assess overall QOL and 24 items for general health having four major domains i.e., physical health, psychological health, social relationships, and environmental health. Each item is rated on a 5-point Likert scale ranging from 1 to 5. Higher scores indicate a higher quality of life. The Urdu version of WHQOL-B has an internal consistency of 0.86 and for subdomains is 0.78, 0.75, and 0.73, respectively.

Randomization

All the respondents were randomly allocated to experimental and waitlist-control groups with an equal ratio of 1:1. To achieve this goal, we generated a randomization schedule using permuted block randomization so that each block contained a random assignment to each of the two groups (see Fig. 1).

Interventions

Antiretroviral Therapy (ART)

Antiretroviral therapy (ART) reduces HIV replication and the infection of new cells and improves immune system function. ART has dramatically reduced HIV-related morbidity and mortality; as a result, the life expectancy of individuals with HIV/AIDS is increasing [65]. HIV is a debilitating disease; however, antiretroviral treatment (ART) helps promote effective viral suppression, reduces transmission risk, and prevents death [66]. In the present study, we did not actively provide ART therapy per se, however, we only took those patients with HIV/AIDS who were already receiving ART therapy as our participants.

Brief-cognitive behavior therapy (B-CBT)

We developed an 8-session brief CBT or B-CBT to be an effective treatment addressing psychiatric symptoms and psychoeducation. Patients with HIV/AIDS usually perceive stigma, decreased quality of life and emotional disturbance, leading to low motivation and a lack of interest in treatment. Our B-CBT aimed at effectively dealing with depressive symptoms, enhancing motivation, and reducing stigma through psychoeducation, cognitive restructuring, skill training, stress management, and relapse prevention [31]. Our B-CBT was aimed to be helpful for patients with HIV/AIDS in order to educate them about the significance of medication and to motivate them to cope with their emotional problems, ultimately enhancing treatment adherence [30]. Other studies have also suggested that B-CBT has proved to be a feasible, acceptable, and promising treatment approach for patients with HIV/AIDS [41]. Our B-CBT also aimed at being an effective psychotherapy to address emotional disturbance among HIV/AIDS patients within 8 session timeframe [33]. The treatment protocol of our 8-session B-CBT was designed as a synthesis of the classic CBT and other B-CBT approaches [53, 54] (See Supplementary File-Table A).

Procedure

In this study, all procedures were approved by the Institutional Review Board (IRB) of Government College University, Faisalabad. We assigned the participants to each treatment condition through randomization to ensure the numbers allocated to each group were comparable and balanced. Participants were recruited from the OPD of THQ Hospital, Shahkot. One of our psychotherapists

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 6 of 13

would start-off by briefly explained to the subjects about the study. Participants would then be tentatively included if thy gave verbal consent. Then, the therapist would describe confidentiality, and a consent form would be given to the participants to sign. After signing the informed consent form, the participants would proceed towards the initial assessment process. Then (after initial assessment and eligibility check) the patients with HIV/AIDS would be randomly assigned to treatment conditions (i.e., B-CBT) and waitlist control. Then we would use different scales to determine the treatment outcomes at pre- and post-assessment i.e., PHQ-9, HIVSS, GMAS, MSPSS, WHOQOL BREF.

Statistical analysis

Descriptive statistics (Mean &SD) were used to calculate sample demographic characteristics. We used t-test and chi-square test of the scales used at baseline assessment stage to make the group matchable and comparable on the variables of concern. After the conclusion of the trial, repeated measures ANOVA was used to investigate the differences between groups, time, and group x time interaction. Frequency distribution statistics were also used to find out the depression and level of social support after treatment. An alpha of 0.05 was used for all analyses, and p-values < 0.05 were submitted to Bonferroni correction using IBM SPSS Statistics (Version 26).

Results

Recruitment and attrition

In this clinical trial, 186 respondents were assessed for eligibility; 60 out of 186 were excluded due to inclusion and exclusion criteria, and 126 met the inclusion criteria then they were allocated to the EXPg ($n = 63(50\%)$) and WLCg ($n = 63(50\%)$) through random assignment (see Fig. 1). We investigated no significant difference at baseline between the EXPg vs. WLCg. Participants were all literate people (the word matric. is a short form of the word matriculation which means 10th grade in Pakistan). Participants' age range was from 20 to 55 years including both men ($n = 52$) and women ($n = 74$) with single ($n = 19$) and married ($n = 107$) marital status. Baseline discrepancies were all insignificant among demographic characteristics and were as follows: age, monthly income, age at diagnosis, gender, education, birth order, marital status, family system, reason of HIV/AIDs, duration of HIV/AIDs diagnosis, duration of HIV/AIDs medication, family members died due to HIV/AIDs, any other family member diagnosed with HIV/AIDs, information about HIV/AIDs, and medication dose irregularity (see Table 1).

Findings show that there is a significant mean difference in the baseline scores and post-testing scores among two groups on PHQ-9 which reflects that almost 0.60% CBT reduced the symptoms severity of depressive symptoms in the EXPg. Similarly, significant mean scores difference was found between EXPg and WLCg on PSS, DSS, NSI, PAS, and overall HIV stigma scale. This indicates that CBT played substantial role to address PSS 0.66%, DSS 0.73%, NSI 0.77%, PAS 0.68%) and HIVS 0.79%. In addition, significant difference was seen on GMAS which reflects that 0.51% CBT enhanced the level of medical adherence in EXPg as compared to WLCg. Findings supported that CBT positively enhanced the degree SOS 0.46%, FAS 0.45%, FRS 0.32% and overall social support 0.61% in EXPg. Furthermore, treatment condition produced significant difference on GHS 0.46%, PHS 0.66%), PSS 0.59%, SRS 0.77%, ESN.66% and overall QOLB 0.83% respectively (see Table 2).

Findings indicate a significant mean difference (i.e., M(SD) on PHQ at post-analysis in the experimental group vs. waitlist control (i.e., 1.22(0.47) vs. 2.30(0.68). Moreover, participants who got CBT eventually had a significant decrease in the severity of their symptoms on PHQ. For example, at the pre-test, the number of participants that had mild symptoms was 3(7.5%), moderate 13(32.5%), moderate-severe 17(42.5%), and severe 7(17.5%), whereas, at post-test the number of participants who had mild symptoms was 32(80.0%), moderate 7(17.5%), moderate-severe 1(2.5%) and nobody was there with severe symptom severity. This indicates a significant change (reduction) in symptoms severity when comparing pre- and post-test scenarios. In contrast, the participants' symptoms severity remains almost the same in the waitlist control when seen in relation with pre- and post-test. Similarly, a significant mean difference was observed in MPSS at post-test in the experimental group vs. waitlist control (i.e., 2.85(0.36) vs. 1.70(0.51), which indicates that participants had an increase in their level of perceived social support after treatment. For example, in the pre-test, participants perceived low 17(42.5%) and moderate 23(57.5%) social support, while in the post-test, 6(15%) participants perceived moderate social support and 34(85%) perceived high social support but in the waitlist-control group remain almost same score at pre- and post-test scenarios (see Table 3).

Results show that depression was significantly reduced on PHQ after receiving B-CBT intervention in HIV/AIDS patients, and post-test analysis showed a significant change in depressive symptoms. Patients reported improvement in the pre-and post-testing of PHQ-9 among the experimental group. On the other hand, no significant difference was found on the pre and post-testing of PHQ-9 among the control group. It indicates that

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 7 of 13

Table 1 Comparison of participants' demographic characteristics group-wise and overall

Variables Characteristics	Category	Overall	Groups Experimental	Control	χ2/t	p
N Allocated		126	63(50.0%)	63(50.0%)		
N Dropout		46	23(50.0%)	23(50.0%)		
N Final		80	40(50.0%)	40(50.0%)		
Age		126	31.87(8.35)	31.93(8.53)	-.042	.846
Monthly Income M(SD)		126	16,857.14(8153.48)	15,476.19(6951.11)	1.023	.380
Gender	Male (n%)	52	25(39.7%)	27(42.9%)	.131	.717
	Female (n%)	74	38(60.3%)	36(57.1%)		
Education	< Matric.(n%)	72	35(55.6%)	37(58.7%)	.376	.829
	Matric. (n%)	33	18(28.6%)	15(23.8%)		
	> Matric. (n%)	21	10(15.9%)	11(17.5%)		
Birth Order	First (n%)	26	14(22.2%)	12(19.0%)	1.004	.605
	Other (n%)	80	41(65.1%)	39(61.9%)		
	Last (n%)	20	8(12.7%)	12(19.0%)		
Marital Status	Married (n%)	107	52(82.5%)	55(87.3%)	.558	.455
	Single (n%)	19	11(17.5%)	8(12.7%)		
Family System	Nuclear (n%)	77	41(65.1%)	36(57.1%)	.835	.361
	Joint (n%)	49	22(34.9%)	27(42.9%)		
Reason of HIV/AIDS	Don't Know (n%)	81	38(60.3%)	43(68.3%)	1.052	.591
	Used syringe (n%)	37	20(31.7%)	17(27.0%)		
	Blood Transfusion (n%)	8	5(7.9%)	3(4.8%)		
Duration of HIV/AIDS diagnosis	1 Month to 1.5 years (n%)	83	41(65.1%)	42(66.7%)	.155	.925
	< 2.5 year (n%)	36	18(28.6%)	18(28.6%)		
	> 3.5 years (n%)	7	4(6.3%)	3(4.8%)		
Duration of HIV/AIDS medication	1 Month to 1.5 years (n%)	84	42(66.7%)	42(66.7%)	.171	.918
	< 2.5 year (n%)	35	17(27.0%)	18(28.6%)		
	> 3.5 years (n%)	7	4(6.3%)	3(4.8%)		
Age at diagnosis		126	30.59(8.11)	30.67(8.47)	-.054	.766
A family member died due to HIV/AIDS	Yes (n%)	117	57(90.5%)	60(95.2%)	1.077	.299
	No (n%)	9	6(9.5%)	3(4.8%)		
Any other family member diagnosed with HIV/AIDS	Yes (n%)	79	41(65.1%)	38(60.3%)	.305	.581
	No (n%)	47	22(34.9%)	25(39.7%)		
Information about HIV/AIDS	Don't Know (n%)	106	51(81.0%)	55(87.3%)	.951	.329
	Know (n%)	20	12(19.0%)	8(12.7%)		
Medication dose Irregularity	No (n%)	81	39(61.9%)	42(66.7%)	.311	.577
	Yes (n%)	45	24(38.1%)	21(33.3%)		

intervention was effective for reducing depression among HIV/AIDS Patients (Fig. 2).

Results show that medication adherence was significantly increased on GMAS after receiving CBT intervention among HIV/AIDS patients, and post-test analysis shows a significant change in medication adherence. Patients reported improvement in the pre- and post-testing of GMAS among the experimental group. On the other hand, no significant difference was found on the pre- and post-testing of GMAS among the control group. It indicates that intervention was effective

for enhancing medication adherence among HIV/AIDS Patients (Fig. 3).

Discussion

In this clinical trial, we noted that depressive symptoms can be reduced through B-CBT, and concurrently, treatment adherence to ART can also be improved. B-CBT substantially helped address various mental health problems of patients with HIV/AIDs. This indicates that a combination of medicinal treatment (ART) with a psychological intervention (B-CBT) is a better treatment choice for treating

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 8 of 13

Table 2 Mean (standard deviation) and Repeated Measure Design of clinical scores during pre- and post-test intervention

| | Groups | | | | Repeated Measure ANOVA | | | | | | η_p^2 |
| | Experimental Group | | Waitlist Control | | Group | | Time | | Group x Time | | |
	Baseline M(SD)	Post-Test M(SD)	Baseline M(SD)	Post-Test M(SD)	F	p-Value	F	p-Value	F	P-Value	
PHQ-9	11.70(4.23)	3.10(2.79)	9.92(3.42)	9.62(3.20)	13.19	.001	116.57	.001	101.38	.001	.599
PSS	57.92(5.65)	42.67(4.41)	56.52(5.37)	54.35(2.54)	45.87	.001	148.61	.001	83.67	.001	.656
DSS	32.27(2.48)	21.72(2.67)	32.87(2.57)	32.10(1.93)	214.26	.001	206.08	.001	153.53	.001	.725
NSI	42.07(5.31)	22.87(3.93)	40.50(4.01)	39.90(2.92)	124.66	.001	261.14	.001	230.44	.001	.770
PAS	65.05(6.33)	48.12(5.05)	63.70(4.86)	61.25(2.73)	54.88	.001	162.19	.001	90.52	.001	.675
HIVS	128.50(9.12)	87.32(8.28)	126.85(9.22)	123.52(6.27)	171.90	.001	288.11	.001	208.42	.001	.787
NAPA	13.65(2.19)	16.43(2.82)	13.70(2.19)	13.65(1.99)	9.18	.003	27.66	.001	29.73	.001	.262
NADP	11.73(2.45)	14.43(2.28)	11.75(2.46)	11.83(2.49)	5.88	.018	173.66	.001	155.39	.001	.690
GMAS	25.38(3.06)	30.85(3.78)	25.45(2.96)	25.47(3.02)	16.56	.001	78.79	.001	77.36	.001	.503
SOS	4.31(1.57)	6.58(.47)	4.30(1.44)	4.85(.89)	19.12	.001	66.71	.001	24.87	.001	.461
FAS	2.76(1.20)	5.71(1.20)	3.00(1.25)	2.55(1.12)	45.19	.001	63.50	.001	117.44	.001	.449
FRS	2.66(1.38)	5.10(1.68)	2.44(1.16)	2.21(.91)	45.23	.001	36.36	.001	53.25	.001	.318
MSSS	3.25(.82)	5.80(.74)	3.25(.95)	3.20(.67)	87.30	.001	119.83	.001	128.33	.001	.606
GHS	5.72(1.28)	9.00(.93)	6.00(1.19)	4.95(.87)	88.26	.001	66.65	.001	251.83	.001	.461
PHS	14.00(1.47)	17.85(1.28)	14.36(1.77)	13.18(1.08)	76.92	.001	150.22	.001	71.11	.001	.658
PSS	13.30(1.86)	17.62(1.70)	13.96(1.98)	12.30(1.28)	79.14	.001	110.28	.001	21.82	.001	.586
SRS	12.05(1.66)	18.35(1.74)	11.65(1.74)	10.30(1.39)	222.11	.001	265.77	.001	111.27	.001	.773
ESN	14.85(1.36)	17.38(1.09)	15.31(1.55)	13.66(1.14)	51.99	.001	128.40	.001	5.73	p001	.662
QOLB	71.65(6.02)	93.05(3.51)	73.80(7.83)	65.75(4.13)	156.97	.001	373.39	.001	76.73	.001	.827

η_p^2 Partial Squared Eta, *PHQ* Patient Health questionnaire, *PSS* Personalized Stigma Subscale, *DSS* Disclosure Subscale, *NSI* Negative Self Image, *PAS* Public Attitudes Subscale, *HIVS* HIV Stigma Scale, *NAPA* Non-adherence due to Patient Behavior, *NADP* Non-adherence due to Additional Disease and Pill Burden, *GMAS* General Medication Adherence Scale, *SOS* Significant other subscales, *FAS* Family Subscale, *FRS* Friends Subscale, *MSSS* Multidimensional Social Support Scale, *GHS* General Health Subscale, *PHS* Physical Health Subscale, *PSS* Psychological Subscale, *SRS* Social Relationship Subscale, *ENS* Environmental Subscale, *QOLB* Quality of Life Brief

Table 3 Comparison of depression and social support levels of severity group-wise and overall

| | Groups | | | |
| Characteristics | Experimental | | Waitlist Control | |
	Pre-Test M(SD)	Post-Test	Pre-Test M(SD)	Post-Test
PHQ M(SD)	2.70(.85)	1.22(.47)	2.42(.67)	2.30(.68)
Mild (%)	3(7.5%)	32(80.0%)	1(2.5%)	4(10.0%)
Moderate (%)	13(32.5%)	7(17.5%)	24(60.0%)	21(52.5%)
Mod. Severe (%)	17(42.5%)	1(2.5%)	12(30.0%)	14(35.0%)
Severe (%)	7(17.5%)	–	3(7.5%)	1(2.5%)
MPSS M(SD)	1.57(.50)	2.85(.36)	1.57(.50)	1.70(.51)
Low support (%)	17(42.5%)	–	17(42.5%)	13(32.5%)
Mod. Support (%)	23(57.5%)	6(15.0%)	23(57.5%)	26(65.0%)
High Support (%)	–	34(85.0%)	–	1(2.5%)

PHQ Patient Health Questionnaire, *MSS* Multidimensional Perceived Social Support Scale

patients with HIV/AIDS as compared with care as usual [41]. Patients with depressive symptoms were seen as more reluctant toward treatment due to a lack of interest and hopelessness in life; they were less motivated to take part in treatment, but we observed that B-CBT significantly reduced their distress, and they showed interest in treatment and started to live with positive hopes towards life [67, 68]. Alongside HIV/AIDs and related medical problems, mental health problems also play a significant role in treatment and recovery. For example, lack of social support, social stigma, family attitude, marital issues, financial strains, and treatment advancement can cause depression and ultimately treatment non-adherence [69–71]. B-CBT protocol helped the patients by providing psychoeducation, creating awareness, developing hope toward life, and reducing emotional disturbance through the therapeutic process using different techniques and skill training.

Moreover, our study's findings indicate that reduction in depressive symptoms and perceived stigma significantly improved treatment adherence [72, 73]. Stigma is seen as a primary concern for people living with (HIV/AIDS), and this has a great negative impact on their quality of life and family relationships, which is a significant cause of psychiatric problems [74]. People with HIV/AIDs feel suppressed and guilty because of their illness, which hurts them internally and this could lead them towards

Abbas *et al. BMC Psychiatry* (2023) 23:539

Page 9 of 13

Fig. 2 Score difference of pre and post-test analysis on PHQ between EXPg vs. WLCg

Fig. 3 Score difference of pre and post-test analysis on GMAS between EXPg vs. WLCg

depression and stigmatization [75]. CBT remained an effective treatment to improve treatment adherence [76, 77]. We observed that some patients were not using proper medications and missed or delayed the recommended doses due to a lack of awareness and misconceptions about the medication and treatment outcomes; after B-CBT, significant positive change in patients' attitudes and behavior toward treatment was observed. Some other issues, such as the number of medications, complex

dosage schedules, and medication side effects reduce treatment adherence. After the B-CBT sessions, significant change in these problems was observed [78, 79].

Furthermore, study findings reported that participants perceived low social support at the baseline due to social stigma and depressive symptoms. However, after B-CBT treatment, participants perceived a significant positive change in social support [80, 81]. When we educate the patients and train them through role plays, they try

to look forward to different opportunities of social connection, they try to improve their social support system, and they also try to talk to others to become more comfortable with them. This could be the reason of reduction in their stigma and depression [82, 83]. Increasing social support among patients also tends to improves quality of life and communication with friends and family members; thereby decreasing the number of depressive symptoms and perceived self-based stigma [84, 85]. During B-CBT treatment, we planned different activities to engage the patients in social communication to reduce their perceived stigma and loneliness; these things brought a positive change in participants' attitudes and behavior. We also designed some other helpful activities for them like: priority setting, decision making, life skill training, and muscle-relaxation training etcetera [80, 86].

Furthermore, when the patients felt relaxed mentally, and believed that medication and therapeutic training are important to manage daily routines and treatment procedures, they took their medication regularly and increased their interest in the treatment [42, 87]. The aspects we observed among the participants who received B-CBT were significantly different compared to WLC [88]. B-CBT appeared to be a successful treatment intervention in increasing quality of life and satisfaction with life and reducing anxiety and depression symptoms [89, 90]. Findings also reveal that B-CBT was an effective therapy to improve the quality of life and overall psychological well-being of patients with HIV/AIDs [91].

Limitations of the study

This study has valuable insights; however, it also has some limitations. In this study, only those patients who were availing outpatient facility were included, and patients in the inpatient setting were excluded from the study. Participants with medical comorbidities were also excluded; therefore, the findings of this study might not be applicable to the patients with HIV/AIDS with other medical comorbidities. Furthermore, in Pakistan, psychological treatment is not very common and is not frequently used in many settings; therefore, most of the Pakistani population is not familiar with this kind of treatment. This was a major limitation when we tried to talk with the patients. Most of them did not know what psychological treatment is, and some left the treatment just because there was no medication involved in it for their psychological complaints. Another limitation of this study was that pregnant women were not studied.

Recommendations

Overall, the study discovered the impact of cognitive behavior therapy on reducing stigma and sadness and improving social support, quality of life, and treatment adherence among patients with HIV/AIDS on antiretroviral therapy (ART). According to our study, it is hereby recommended to note which other factors influence the development and strengthening of therapeutic alliances during HIV/AIDS treatment. Also, it should also be explored why do patients terminate their treatment?. Further, the complex interaction between transference and therapeutic alliance is not clear. We tried to explore this complex relationship during treatment. However, it was beyond the reach of any therapist to find all factors that may influence an outcome at a time, so further research should be done to investigate the other factors.

Further research may include more patients in the form of a larger sample size. Further, most of the previous studies were done in Western countries, and very few people in Pakistan know how to manage the disease, so there still is a need to conduct studies in the south Asian culture, especially in underdeveloped countries like Pakistan. Hence, further research is required in these places because the rate of depression and psychological distress, negative thinking, add to the suffering of the in patients with HIV/AIDS, and also because the disease is spreading at a higher pace than before. The overall current study showed good and fruitful results. It is important to note patients, with some help from a psychotherapist, can independently manage their problems and the level of depression through cognitive behavioral therapy. Further research work on the ART side-effects that result in medication and a need to manage it is needed.

The implication of the study

This study could be used in hospitals to help doctors treat patients with HIV/AIDS and to promote the knowledge and management skills to address mental health problems. Therefore, to improve patients' mental health and wellness, we must create a separate place/counseling room in each HIV/AIDS hospital where patients' confidence can be maintained. This study is conducted with HIV/AIDS patients, and it is the first clinical trial in Pakistan; the study findings should be important for policy-making, preparing treatment protocols, and treating patients with HIV/AIDS. The study provides the basis for introducing psychological or counseling intervention to address the mental and physiological health of patients with HIV/AIDS.

Conclusion

This clinical trial successfully addressed many psychological problems and low adherence to treatment using B-CBT in patients with HIV/AIDS who were availing ART treatment in a hospital. B-CBT significantly reduced

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 11 of 13

depressive symptoms and emotional disturbance, which maybe were, due to social stigma, hence, a substantial improvement was seen in social support and quality of life. Furthermore, B-CBT produced significant and reliable outcomes addressing mental health problems using effective modalities to guide the patients and understand the significance of psychological treatment addressing the problems of patients with HIV/AIDs and has shown to be a supportive intervention of choice for such patients.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12888-023-05013-2.

Additional file 1.

Availability of data and materials
The dataset generated and/or analyzed during the present study is not publicly available because no permission was taken from the participants and the hospital administration where the study was conducted. The datasets are available from the corresponding authors upon request.

Declarations

Ethics approval and consent to participate
Ethical approval was taken from the Institutional Review Board (IRB), Government College University, Faisalabad, Pakistan (i.e. Ref.No. GCUF/ERC/2267, dated 17/06/2021), and then the protocol was approved by the Thai clinical trial registry (i.e. TCTR = TCTR20210702002, with URL: https://www.thaiclinicaltrials.org/show/TCTR20210702002), with first registration date 02/07/2021. Participants gave written informed consent before the process of enrollment and screening. All procedures were performed under relevant guidelines, including participant enrollment, screening, data collection, data scrutiny, and analysis. We followed the Consolidated Standards of Reporting Trials CONSORT reporting guidelines. Furthermore, we confirm that all of the procedure and methods of this study were executed by adhering to the requirements of our institutional review board, and the global code of conduct for research in resource-poor settings.

Consent for publication
Not applicable.

Author details
[1]Department of Applied Psychology, Government College University Faisalabad, Main Campus, Faisalabad, Punjab, Pakistan. [2]Dow International Medical College, Dow University of Health Sciences, Karachi, Pakistan. [3]Department of Psychiatry, College of Medicine, Qassim University, Buraydah, Saudi Arabia.

References
1. Brandt C, Zvolensky MJ, Woods SP, Gonzalez A, Safren SA, O'Cleirigh CM. Anxiety symptoms and disorders among adults living with HIV and AIDS: a critical review and integrative synthesis of the empirical literature. Clin Psychol Rev. 2017;51:164–84.
2. Shidiq KM, Nelwan EJ, Yunihastuti E, Harimurti K, Pohan HT. Clinical Evaluation of HIV/AIDS patients on antiretroviral therapy using HIV symptoms index: a reliability and applicability evaluation using Indonesian language. Acta Medica Indones. 2021;53:52–9.
3. Yin L, Wang N, Vermund SH, Shepherd BE, Ruan Y, Shao Y, et al. Sexual risk reduction for hiv-infected persons: a meta-analytic review of "positive prevention" randomized clinical trials. PLoS ONE. 2014;9: e107652.
4. Nikooseresht Z, Rimaz S, Asadi-Lari M, Nedjat S, Merghati-Khoee E, Saiepour N. Reliability and validity of the Iranian version of the human immunodeficiency virus specific World Health Organization quality of life BREF questionnaire. J Biostat Epidemiol. 2015;1:37–44.
5. Rendina HJ, Gamarel KE, Pachankis JE, Ventuneac A, Grov C, Parsons JT. Extending the minority stress model to incorporate hiv-positive gay and bisexual men's experiences: a longitudinal examination of mental health and sexual risk behavior. Ann Behav Med. 2017;51:147–58.
6. Bayat A-H, Mohammadi R, Moradi-Joo M, Bayani A, Ahounbar E, Higgs P, et al. HIV and drug related stigma and risk-taking behaviors among people who inject drugs: a systematic review and meta-analysis. J Addict Dis. 2020;38:71–83.
7. Bogart LM, Wagner GJ, Galvan FH, Landrine H, Klein DJ, Sticklor LA. Perceived discrimination and mental health symptoms among Black men with HIV. Cultur Divers Ethnic Minor Psychol. 2011;17:295–302.
8. Earnshaw VA, Bogart LM, Dovidio JF, Williams DR. Stigma and racial/ethnic HIV disparities: Moving toward resilience. Stigma Health. 2015;1 S:60–74.
9. Herek GM, Capitanio JP. Public reactions to AIDS in the United States: a second decade of stigma. Am J Public Health. 1993;83:574–7.
10. Gesesew HA, Gebremedhin AT, Demissie TD, Kerie MW, Sudhakar M, Mwanri L. Significant association between perceived HIV related stigma and late presentation for HIV/AIDS care in low and middle-income countries: a systematic review and meta-analysis. PLoS ONE. 2017;12: e0173928.
11. Rueda S, Mitra S, Chen S, Gogolishvili D, Globerman J, Chambers L, et al. Examining the associations between HIV-related stigma and health outcomes in people living with HIV/AIDS: a series of meta-analyses. BMJ Open. 2016;6: e011453.
12. UNAIDS Fact Sheet 2023 Global HIV Statistics. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf.
13. Arseniou S, Arvaniti A, Samakouri M. HIV infection and depression. Psychiatry Clin Neurosci. 2014;68:96–109.
14. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry. 2003;54:295–306.
15. Owe -Larsson B., Sall L, Salamon E, Allgulander C. HIV infection and psychiatric illness : review article. Afr J Psychiatry. 2009;12:115–28.
16. Tesfaw G, Ayano G, Awoke T, Assefa D, Birhanu Z, Miheretie G, et al. Prevalence and correlates of depression and anxiety among patients with HIV on-follow up at Alert Hospital, Addis Ababa. Ethiopia BMC Psychiatry. 2016;16:368.
17. Junaid K, Ali H, Khan AA, Khan TA, Khan AM, Khan A, et al. Prevalence and Associated Factors of Depression among Patients with HIV/AIDS in Lahore, Pakistan: Cross-Sectional Study. Psychol Res Behav Manag. 2021;14:77–84.

18. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, et al. Association Between Use of Specific Drugs and Antiretroviral Adherence: Findings from MACH 14. AIDS Behav. 2013;17:142–7.

19. Armoon B, Higgs P, Fleury M-J, Bayat A-H, Moghaddam LF, Bayani A, et al. Socio-demographic, clinical and service use determinants associated with HIV related stigma among people living with HIV/AIDS: a systematic review and meta-analysis. BMC Health Serv Res. 2021;21:1004.

20. Gitahi N, Wahome S, Bukusi EA, Memiah P. The role of self-efficacy in HIV treatment adherence and its interaction with psychosocial factors among HIV positive adolescents in transition to adult care in Kenya. Vulnerable Child Youth Stud. 2021;0:1–12.

21. Yu Y, Luo D, Chen X, Huang Z, Wang M, Xiao S. Medication adherence to antiretroviral therapy among newly treated people living with HIV. BMC Public Health. 2018;18:825.

22. DeFulio A, Devoto A, Traxler H, Cosottile D, Fingerhood M, Nuzzo P, et al. Smartphone-based incentives for promoting adherence to antiretroviral therapy: a randomized controlled trial. Prev Med Rep. 2021;21: 101318.

23. Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status, and association with sustained HIV viral suppression among adults living with hiv in care in the United States, 2009–2014. AIDS Behav. 2019;23:3452–9.

24. Wohl AR, Galvan FH, Myers HF, Garland W, George S, Witt M, et al. Social Support, Stress and Social Network Characteristics Among HIV-Positive Latino and African American Women and Men Who have Sex with Men. AIDS Behav. 2010;14:1149–58.

25. Yadav S. Perceived social support, hope, and quality of life of persons living with HIV/AIDS: a case study from Nepal. Qual Life Res. 2010;19:157–66.

26. Oetzel J, Wilcox B, Archiopoli A, Avila M, Hell C, Hill R, et al. Social support and social undermining as explanatory factors for health-related quality of life in people living with HIV/AIDS. J Health Commun. 2014;19:660–75.

27. Burgoyne RW. Exploring direction of causation between social support and clinical outcome for HIV-positive adults in the context of highly active antiretroviral therapy. AIDS Care. 2005;17:111–24.

28. Bhatta DN, Liabsuetrakul T, McNeil EB. Social and behavioral interventions for improving quality of life of HIV infected people receiving antiretroviral therapy: a systematic review and meta-analysis. Health Qual Life Outcomes. 2017;15:80.

29. Mwesiga EK, Mugenyi L, Nakasujja N, Moore S, Kaddumukasa M, Sajatovic M. Depression with pain co morbidity effect on quality of life among HIV positive patients in Uganda: a cross sectional study. Health Qual Life Outcomes. 2015;13:206.

30. Samaan M, Diefenbacher A, Schade C, Dambacher C, Pontow I-M, Pakenham K, et al. A clinical effectiveness trial comparing ACT and CBT for inpatients with depressive and mixed mental disorders. Psychother Res. 2021;31:372–85.

31. Cuijpers P, Karyotaki E, de Wit L, Ebert DD. The effects of fifteen evidence-supported therapies for adult depression: a meta-analytic review. Psychother Res. 2020;30:279–93.

32. Andersen LS, Magidson JF, O'Cleirigh C, Remmert JE, Kagee A, Leaver M, et al. A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South Africa. J Health Psychol. 2018;23:776–87.

33. Harkness A, Rogers BG, Puccinelli M, Ivardic I, Ironson G, Safren SA. Engaging, retaining, and providing transdiagnostic integrated cognitive–behavioral therapy and motivational interviewing for underserved people with HIV. Psychotherapy. 2020;57:15–22.

34. Safren SA, O'Cleirigh C, Andersen LS, Magidson JF, Lee JS, Bainter SA, et al. Treating depression and improving adherence in HIV care with task-shared cognitive behavioural therapy in Khayelitsha, South Africa: a randomized controlled trial. J Int AIDS Soc. 2021;24: e25823.

35. Folkman S, Chesney M, McKusick L, Ironson G, Johnson DS, Coates TJ. Translating coping theory into an intervention. In: The social context of coping. Springer; 1991. p. 239–60.

36. Cruess S, Antoni MH, Hayes A, Penedo F, Ironson G, Fletcher MA, et al. Changes in mood and depressive symptoms and related change processes during cognitive–behavioral stress management in HIV-infected men. Cogn Ther Res. 2002;26:373–92.

37. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28:1–10.

38. Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. Ann Behav Med. 2011;41:83–91.

39. Spies G, Asmal L, Seedat S. Cognitive-behavioural interventions for mood and anxiety disorders in HIV: A systematic review. J Affect Disord. 2013;150:171–80.

40. Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. Lancet HIV. 2016;3:e529–38.

41. Han S, Hu Y, Lu H, Zhang L, Zhu Z, Luo J, et al. Cognitive behavioral therapy for persons living with HIV in China: a randomized pilot trial. J Affect Disord. 2020;277:640–8.

42. van Luenen S, Garnefski N, Spinhoven P, Spaan P, Dusseldorp E, Kraaij V. The benefits of psychosocial interventions for mental health in people living with HIV: a systematic review and meta-analysis. AIDS Behav. 2018;22:9–42.

43. Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther. 2004;9:85–95.

44. Johnson MO, Gamarel KE, Dawson RC. Changing HIV treatment expectancies: a pilot study. AIDS Care. 2006;18:550–3.

45. Zilber C. Psychotherapeutic Strategies. In: Psychiatric aspects of HIV/AIDS. Philadelphia, PA, US: Lippincott Williams & Wilkins Publishers; 2006. p. 355–64.

46. Crepaz N, Passin WF, Herbst JH, Rama SM, Malow RM, Purcell DW, et al. Meta-analysis of cognitive-behavioral interventions on HIV-positive persons' mental health and immune functioning. Health Psychol. 2008;27:4–14.

47. Himelhoch S, Medoff DR, Oyeniyi G. Efficacy of Group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDs. 2007;21:732–9.

48. Zhang A, Froerer A. A Clinical Case Study of Solution-Focused Brief Therapy for Young Adult Cancer Patients' Psychological Distress: Focusing on Positive Emotions. Clin Case Stud. 2023;0(0). OnlineFirst https://doi.org/10.1177/15346501231161776.

49. Graboyes EM, Maurer S, Balliet W, Li H, Williams AM, Osazuwa-Peters N, et al. Efficacy of a brief tele-cognitive behavioral treatment vs attention control for head and neck cancer survivors with body image distress: a pilot randomized clinical trial. JAMA Otolaryngol Neck Surg. 2023;149:54–62.

50. Bryan CJ, Carpenter KM, Pawlik TM. Evidence-based strategies to reduce suicide mortality among patients with cancer. JAMA Oncol. 2023;9(3):303–4. https://doi.org/10.1177/153465012311617.

51. Abbas Q, Arooj N, Baig KB, Khan MU, Khalid M, Shahzadi M. A clinical trial of cognitive behavior therapy for psychiatric comorbidity and quality of life with Cancer Patients during Chemotherapy (CPdC). BMC Psychiatry. 2022;22:1–9.

52. Naeem F, Latif M, Mukhtar F, Kim Y-R, Li W, Butt MG, et al. Transcultural adaptation of cognitive behavioral therapy (CBT) in Asia. Asia-Pac Psychiatry. 2021;13: e12442.

53. Bond (Editor) FW, Dryden (Editor) W. Handbook of Brief Cognitive Behaviour Therapy. 1st edition. John Wiley & Sons Ltd.; 2004.

54. Beck JS. Cognitive Behavior Therapy, Third Edition: Basics and Beyond. Guilford Publications; 2020.

55. Khurshid K, Dutta T, Khan KS, Haider SA, Ahmed UA, Jatoi H, et al. Addressing stigma among persons living with HIV through the Sujaag project in Pakistan: a socioecological analysis. J Soc Issues. 2023;79:446–64.

56. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009;41:1149–60.

57. Ahmad S, Hussain S, Akhtar F, Shah FS. Urdu translation and validation of PHQ-9, a reliable identification, severity and treatment outcome tool for depression. J Pak Med Assoc. 2018;68:5.

58. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9. J Gen Intern Med. 2001;16:606–13.

Abbas *et al. BMC Psychiatry*   (2023) 23:539

Page 13 of 13

59. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: Psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24:518–29.

60. Saif S, Shahzad S. Urdu translation and adaptation of the HIV stigma scale in Pakistan injectable drug users with HIV. J Pak Med Assoc. 2020;70:505–10. https://doi.org/10.5455/JPMA.19937.

61. Naqvi AA, Hassali MA, Rizvi M, Zehra A, Iffat W, Haseeb A, et al. Development and validation of a novel General Medication Adherence Scale (GMAS) for chronic illness patients in Pakistan. Front Pharmacol. 2018;9:1124.

62. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional scale of perceived social support. J Pers Assess. 1988;52:30–41.

63. Akhtar A, Rahman A, Husain M, Chaudhry IB, Duddu V, Husain N. Multidimensional scale of perceived social support: Psychometric properties in a South Asian population. J Obstet Gynaecol Res. 2010;36:845–51.

64. Lodhi FS, Raza O, Montazeri A, Nedjat S, Yaseri M, Holakouie-Naieni K. Psychometric properties of the Urdu version of the World Health Organization's quality of life questionnaire (WHOQOL-BREF). Med J Islam Repub Iran. 2017;31:129.

65. Yoshimura K. Current status of HIV/AIDS in the ART era. J Infect Chemother. 2017;23:12–6.

66. Holmes CB, Rabkin M, Ford N, Preko P, Rosen S, Ellman T, et al. Tailored HIV programmes and universal health coverage. Bull World Health Organ. 2020;98:87–94.

67. Jayasvasti I, Hiransuthikul N, Pityaratstian N, Lohsoonthorn V, Kanchanatawan B, Triruangworawat B. The effect of cognitive behavioral therapy and changes of depressive symptoms among Thai adult hiv-infected patients. World J AIDS. 2011;01:15.

68. Yirdaw B. Depression and HIV/AIDS: adapting and piloting group interpersonal therapy for treatment of depressive symptoms for people living with HIV/AIDS in Northwest Ethiopia. Doctoral dissertation. University of Cape Town, Rondebosch; 2021. http://hdl.handle.net/11427/33984.

69. Abadiga M. Depression and its associated factors among HIV/AIDS patients attending ART clinics at Gimbi General hospital, West Ethiopia, 2018. BMC Res Notes. 2019;12:527.

70. Asrat B, Schneider M, Ambaw F, Lund C. Effectiveness of psychological treatments for depressive symptoms among people living with HIV/AIDS in low- and middle-income countries: a systematic review and meta-analysis. J Affect Disord. 2020;270:174–87.

71. Deng X, Jiang W. Evaluating Green Supply Chain Management Practices Under Fuzzy Environment: A Novel Method Based on D Number Theory. Int J Fuzzy Syst. 2019;21:1389–402.

72. Biel D, Carrobles JA, Antón M. Reducing stigma, depression, and anxiety in people with HIV through a cognitive behavioral therapy group. Behav Psychol Conduct. 2021;29:237–57.

73. Yigit I, Bayramoglu Y, Weiser SD, Johnson MO, Mugavero MJ, Turan JM, et al. Changes in Internalized Stigma and HIV Health Outcomes in Individuals New to HIV Care: The Mediating Roles of Depression and Treatment Self-Efficacy. AIDS Patient Care STDs. 2020;34:491–7.

74. Ma PHX, Chan ZCY, Loke AY. Self-stigma reduction interventions for people living with HIV/AIDS and their families: a systematic review. AIDS Behav. 2019;23:707–41.

75. Zhang H, Yu Q, Li Z, Xiu X, Lv F, Han M, et al. Efficacy of psychological interventions towards the reduction of high-risk sexual behaviors among people living with HIV: a systematic review and meta-analysis, 2010–2020. AIDS Behav. 2021;25:3355–76.

76. Bogart LM, Barreras JL, Gonzalez A, Klein DJ, Marsh T, Agniel D, et al. Pilot randomized controlled trial of an intervention to improve coping with intersectional stigma and medication adherence among HIV-positive latinx sexual minority men. AIDS Behav. 2021;25:1647–60.

77. Whiteley LB, Olsen EM, Haubrick KK, Odoom E, Tarantino N, Brown LK. A review of interventions to enhance HIV medication adherence. Curr HIV/AIDS Rep. 2021. https://doi.org/10.1007/s11904-021-00568-9.

78. Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al. Cultural adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. J Health Psychol. 2017;22:1265–76.

79. Doerfler ER, Goodfellow L. Brief exposure to cognitive behavioral therapy reduces side-effect symptoms in patients on antiretroviral therapy. J Assoc Nurses AIDS Care. 2016;27:455–67.

80. LaRocca MA, Scogin FR. The effect of social support on quality of life in older adults receiving cognitive behavioral therapy. Clin Gerontol. 2015;38:131–48.

81. Yang JP, Simoni JM, Dorsey S, Lin Z, Sun M, Bao M, et al. Reducing distress and promoting resilience: a preliminary trial of a CBT skills intervention among recently HIV-diagnosed MSM in China. AIDS Care. 2018;30:S39-48.

82. Ahmed A, Saqlain M, Umair MM, Hashmi FK, Saeed H, Amer M, et al. Stigma, social support, illicit drug use, and other predictors of anxiety and depression among HIV/AIDS patients in Pakistan: a cross-sectional study. Front Public Health. 2021;9:1428.

83. Mo PKH, Chen X, Lam EHK, Li J, Kahler CW, Lau JTF. The moderating role of social support on the relationship between anxiety, stigma, and intention to use illicit drugs among HIV-positive men who have sex with men. AIDS Behav. 2020;24:55–64.

84. Mohr DC, Classen C, Barrera M. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychol Med. 2004;34:533–41.

85. Wen J, Yeh T-P, Xie H, Yu X, Tang J, Chen Y. Resilience, self-esteem, self-efficacy, social support, depression and ART adherence among people living with HIV in Sichuan. China AIDS Care. 2021;33:1414–21.

86. Rasoolinajad M, Abedinia N, Noorbala AA, Mohraz M, Badie BM, Hamad A, et al. Relationship among HIV-related stigma, mental health and quality of life for HIV-positive patients in Tehran. AIDS Behav. 2018;22:3773–82.

87. Mirzaian S. The role of health hardiness and anxiety on immune system and quality of life patients with HIV. J Mod Psychol. 2021;1:25–36.

88. Brandt CP, Paulus DJ, Garza M, Lemaire C, Norton PJ, Zvolensky MJ. A novel integrated cognitive-behavioral therapy for anxiety and medication adherence among persons living with HIV/AIDS. Cogn Behav Pract. 2018;25:105–18.

89. Molavi S, Seraj Khorrami N, Ehteshamzadeh P, Sayyah M. Effectiveness of Mindfulness-Based Cognitive Therapy on Sleep Quality and Perceived Social Support Improvement in Patients with HIV/AIDS. Jundishapur J Chronic Dis Care. 2020;9(1):1–8. https://doi.org/10.5812/jjcdc.99449.

90. Oei TP, McAlinden NM. Changes in quality of life following group CBT for anxiety and depression in a psychiatric outpatient clinic. Psychiatry Res. 2014;220:1012–8.

91. Madhombiro M, Kidd M, Dube B, Dube M, Mutsvuke W, Muronzie T, et al. Effectiveness of a psychological intervention delivered by general nurses for alcohol use disorders in people living with HIV in Zimbabwe: a cluster randomized controlled trial. J Int AIDS Soc. 2020;23: e25641.

Publisher's Note